Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Double-Blind Placebo-controlled Multicentre Phase I Study to Assess the Biological Activity of AZD8931 in Patients With Early Breast Cancer Who Are Ineligible for Treatment With Trastuzumab as Defined by IHC Status

NCT01596530 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01596530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01596530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Double-Blind Placebo-controlled Multicentre Phase I Study to Assess the Biological Activity of AZD8931 in Patients With Early Breast Cancer Who Are Ineligible for Treatment With Trastuzumab as Defined by IHC Status
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Terminated
Start date
June 30, 2012
Completion date
May 31, 2013
Enrollment
3 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasm